Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer
- 1 March 1998
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 48 (1) , 87-92
- https://doi.org/10.1023/a:1005903226483
Abstract
Tamoxifen causes an objective response in about one-third of metastatic breast cancer and in only half of the breast cancer patients with estrogen receptor (ER) positive tumors. Steroid-receptor...Keywords
This publication has 17 references indexed in Scilit:
- A signature motif in transcriptional co-activators mediates binding to nuclear receptorsNature, 1997
- Coactivator and Corepressor Regulation of the Agonist/Antagonist Activity of the Mixed Antiestrogen, 4-HydroxytamoxifenMolecular Endocrinology, 1997
- Antiestrogens: Mechanisms of action and resistance in breast cancerBreast Cancer Research and Treatment, 1997
- Interaction of Steroid Hormone Receptors with the Transcription Initiation ComplexEndocrine Reviews, 1996
- Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.Proceedings of the National Academy of Sciences, 1996
- Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sourcesInternational Journal of Cancer, 1996
- Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor SuperfamilyScience, 1995
- Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancerBritish Journal of Cancer, 1994
- Cell biological factors associated with the response of breast cancer to systemic treatmentCancer Treatment Reviews, 1993
- Identification of mutations leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA.Proceedings of the National Academy of Sciences, 1989